What Aviceda’s lead candidate AVD-104 may mean for dry AMD (ASRS 2020)

July 30, 2020

Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.


Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD, in an interview with Sheryl Stevenson, Ophthalmology Times'® group editorial director, during the virtual 2020 American Society of Glaucoma Specialists (ASRS) annual meeting.

See more ASRS coverage here